Gastroesophageal reflux disease does not lead to changes in the secretory leukocyte protease inhibitor expression in esophageal mucosa

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 2, 2009, Pages 150-158

  Wex, Thomas ^a   Mönkemüller, Klaus ^a   Kuester, Doerthe ^a   Weise, Susanne ^a   Kropf, Siegfried ^a   Fry, Lucia C ^a   Stahr, Antje ^a   Völkel, Simone ^a   Roessner, Albert ^a   Malfertheiner, Peter ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Esophagus; Gastroesophageal reflux disease; Inflammation; Secretory leukocyte protease inhibitor

Indexed keywords

SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SERINE PROTEINASE; RNA;

ADULT; AGED; ARTICLE; BASAL CELL; CHRONIC INFLAMMATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; ENDOSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; ESOPHAGUS MUCOSA; FEMALE; GASTROESOPHAGEAL REFLUX; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH MUCOSA; ADOLESCENT; BIOPSY; ESOPHAGUS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MUCOSA; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOPSY; ESOPHAGOGASTRIC JUNCTION; ESOPHAGUS; FEMALE; GASTROESOPHAGEAL REFLUX; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; MUCOUS MEMBRANE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; YOUNG ADULT;

EID: 59149099258     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32830e4905     Document Type: Article

References (34)

1. Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol 2007; 41:131-137.
2. Goh KL Changing trends in gastrointestinal disease in the Asia-Pacific region. J Dig Dis 2007;8:179-185.
3. Malfertheiner P, Hallerbäck B. Clinical manifestations and complications of gastroesophageal reflux disease (GERD). Int J Clin Pract 2005; 59: 346-355.
4. Vakil N, Van Zanten SV, Kahrilas P, Dent J, Jones R, Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101:1900-1920.
5. Malfertheiner P, Moenkemueller K, Wex T. GERD: endoscopic assessment - a reconcilation with symptoms. J Clin Gastroenterol 2007; 41 (Suppl 2):193-197.
6. Isomoto H, Saenko VA, Kanazawa Y, Nishi Y, Ohtsuru A, Inoue K, et al. Enhanced expression of interleukin-8 and activation of nuclear factor kappa-B in endoscopy-negative gastroesophageal reflux disease. Am J Gastroenterol 2004; 99:589-597.
7. Isomoto H, Kanazawa Y, Nishi Y, Wen CY, Inoue K, Kohno S. Expression of CXC receptor 1 and 2 in esophageal mucosa of patients with reflux esophagitis. World J Gastroenterol 2005; 11:1793-1797.
8. Lurje G, Vallbohmer D, Collet PH, Xi H, Baldus SE, Brabender J, et al. COX-2 mRNA expression is significantly increased in acid-exposed compared to nonexposed squamous epithelium in gastroesophageal reflux disease. J Gastrointest Surg 2007; 11:1105-1111.
9. Roberts NB. Human pepsins - their multiplicity, function and role in reflux disease. Aliment Pharmacol Ther 2006; 24(Suppl 2):2-9.
10. Nagahama K, Yamato M, Nishio H, Takeuchi K. Essential role of pepsin in pathogenesis of acid reflux esophagitis in rats. Dig Dis Sci 2006; 51:303-309.
11. Yoshida N, Katada K, Handa O, Takagi T, Kokura S, Naito Y, et al. Interleukin-8 production via protease-activated receptor 2 in human esophageal epithelial cells. Int J Med Med 2007; 19:335-340.
12. Vieth M, Peitz U, Labenz J, Kulig M, Naucler E, Jaspersen D, et al. What parameters are relevant for the histological diagnosis of gastroesophageal reflux disease without Barrett's mucosa? Dig Dis 2004; 22:196-201.
13. Fitch PM, Roghanian A, Howie SE, Sallenave JM. Human neutrophil elastase inhibitors in innate and adaptive immunity. Bio chem Soc Trans 2006; 34:279-282.
14. Potempa J, Korzus E, Travis J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem 1994; 269:15957-15960.
15. Hiemstra PS, Fernie-King BA, McMichael J, Lachmann PJ, Sallenave JM. Antimicrobial peptides: mediators of innate immunity as templates for the development of novel anti-infective and immune therapeutics. Curr Pharm Des 2004; 10:2891-2905.
16. Hiemstra PS, Maassen RJ, Stolk J, Heinzel-Wieland R, Steffens GJ, Dijkman JH. Antibacterial activity of antileukoprotease. Infect Immun 1996; 64: 4520-4524.
17. Lentsch AB, Jordan JA, Czermak BJ, Diehl KM, Younkin EM, Sarma V, et al. Inhibition of NF-kappaB activation and augmentation of IkappaBbeta by secretory leukocyte protease inhibitor during lung inflammation. Am J Pathol 1999; 154:239-247.
18. Taggart CC, Cryan SA, Weldon S, Gibbons A, Greene CM, Kelly E, et al. Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding. J Exp Med 2005; 202: 1659-1668.
19. Yang J, Zhu J, Sun D, Ding A. Suppression of macrophage responses to bacterial lipopolysaccharide (LPS) by secretory leukocyte protease inhibitor (SLPI) is independent of its anti-protease function. Biochim Biophys Acta 2005; 1745:310-317.
20. Samsom JN, Van der Marel AP, Van Berkel LA, Van Helvoort JM, Simons-Oosterhuis Y, Jansen W, et al. Secretory leukoprotease inhibitor in mucosal lymph node dendritic cells regulates the threshold for mucosal tolerance. J Immunol 2007; 179:6588-6595.
21. Hollander C, Westin U, Wallmark A, Piitulainen E, Sveger T, Janciauskiene SM. Plasma levels of alpha1 -antichymotrypsin and secretory leukocyte proteinase inhibitor in healthy and chronic obstructive pulmonary disease (COPD) subjects with and without severe alphal -antitrypsin deficiency. BMC Pulm Med 2007; 7:1-6.
22. Maruyama M, Sugiyama E, Hori T, Murayama R, Nakazaki S, Yamashita N, et al. Increased serum concentrations of secretory leukoprotease inhibitor in patients with primary Sjögren's syndrome. In vivo 1998; 12:535-538.
23. Grobmyer SR, Barie PS, Nathan CF, Fuortes M, Lin E, Lowry SF, et al. Secretory leukocyte protease inhibitor, an inhibitor of neutrophil activation, is elevated in serum in human sepsis and experimental endotoxemia. Crit Care Med 2000; 28:1276-1282.
24. Wex T, Sokic-Milutinovic A, Todorovic V, Bjelovic M, Milosavljevic T, Pesko P, et al. Down-regulation of secretory leukocyte protease inhibitor expression in gastric mucosa is a general phenomenon in Helicobacter pylori-related gastroduodenal diseases. Dig Dis 2004; 22:390-395.
25. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney system. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20:1161-1181.
26. Wex T, Treiber G, Lendeckel U, Malfertheiner P. A two-step method for the extraction of high-quality RNA from endoscopic biopsies. Clin Chem Lab Med 2003; 41:1033-1037.
27. Hritz I, Kuester D, Vieth M, Herszenyi L, Stolte M, Roessner A, et al. Secretory leukocyte protease inhibitor expression in various types of gastritis: a specific role of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2006; 18:277-282.
28. Wex T, Treiber G, Nilius M, Vieth M, Roessner A, Malfertheiner P. Helicobacter pylori-mediated gastritis induces local downregulation of secretory leukocyte protease inhibitor in the antrum. Infect Immun 2004; 72:2383-2385.
29. Hackelsberger A, Günther T, Schultze V, Labenz J, Roessner A, Malfertheiner P. Prevalence and pattern of Helicobacter pylori gastritis in the gastric cardia. Am J Gastroenterol 1997; 92:2220-2224.
30. El-Serag HB, Graham DY, Rabeneck L, Avid A, Richardson P, Genta RM. Prevalence and determinants of histological abnormalities of the gastric cardia in volunteers. Scand J Gastroenterol 2007; 42:1158-1166.
31. Mohammadi M, Czinn S, Redline R, Nedrud J. Helicobacter-specific cell-mediated immune responses display a predominant Th1 phenotype and promote a delayed-type hypersensitivity response in the stomachs of mice. J Immunol. 1996; 156:4729-4738.
32. Fitzgerald RC, Abdalla S, Onwuegbusi BA, Sirieix P, Saeed IT, Burnham WR, et al. Inflammatory gradient in Barrett's oesophagus: implications for disease complications. Gut 2002; 51:316-322.
33. Lembo T, Ippoliti AF, Ramers C, Weinstein WM. Inflammation of the gastro-oesophageal junction (carditis) in patients with symptomatic gastro-oesophageal reflux disease: a prospective study. Gut 1999; 45:484-488.
34. Guenther T, Hackelsberger A, Kuester D, Malfertheiner P, Roessner A. Reflux esophagitis or Helicobacter infection - diagnostic value of the inflammatory pattern in metaplastic mucosa at the squamocolumnar junction. Pathol Res Pract 2007; 203:831-837.